ProCE Banner Activity

BEe-HIVe: HepB-CpG HBV Vaccine Durability in People Living With HIV on ART ± Prior Vaccine History

Conference Coverage
Slideset

In phase III BEe-HIVe trial, 3-dose HepB-CpG provided more durable seroprotection than HepB-alum or 2-dose HepB-CpG in people living with HIV on ART, regardless of prior vaccination history against HBV.

Released: March 17, 2025

Expiration: September 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare